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d’Oncologia-ICO, IDIBELL, University of Barcelona, Barcelona, SpainAbstractThe purpose of this study was to identify factors inﬂuencing mortality in neutropenic patients with haematologic malignancies or solid
tumours with bloodstream infection (BSI). All episodes of BSI occurring in adult neutropenic patients with haematologic malignancies or
solid tumours were prospectively recorded from January 2006 to December 2013. We analysed the factors inﬂuencing mortality in both
groups of patients. We documented 602 consecutive episodes of BSI; 510 occurred in patients with haematologic malignancies and 92 in
patients with solid tumours. The overall case-fatality rates were 12% and 36%, respectively. Independent risk factors associated with a
higher case-fatality rate in patients with haematologic malignancies were: intensive care unit admission (odds ratio (OR), 15.2; 95%
conﬁdence interval (CI), 5.4–42.7), advanced neoplasm (OR, 8.7; 95% CI, 2.9–25.7), corticosteroid therapy (OR, 7.0; 95% CI, 3–16.4),
multidrug-resistant Gram-negative BSI (OR, 3.8; 95% CI, 1.2–11.8) and a Multinational Association for Supportive Care in Cancer risk
score of <21 (OR, 3.1; 95% CI, 1.3–7.4). By contrast, coagulase-negative staphylococci BSI (OR, 0.04; 95% CI, 0.004–0.5) and empirical
antibiotic combination therapy (OR, 0.1; 95% CI, 0.05–0.3) were found to be protective. Independent risk factors for overall case-fatality
rate in patients with solid tumours were: shock at presentation (OR, 14.3; 95% CI, 3.2–63.8), corticosteroid therapy (OR, 10; 95% CI,
2.3–44) and advanced neoplasm (OR, 7.8; 95% CI, 1.4–41.4). Prognostic factors identiﬁed in this study may help to detect those patients
at higher risk of death in each group. Medical intervention addressing some of these factors might improve the outcome of BSI in
neutropenic patients with haematologic malignancies or solid tumours.
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cancer, and neutropenia is the main risk factor for developing a
serious infection [1]. New strategies regarding biologic thera-
pies and haematopoietic stem cell transplants, as well as
radiotherapy ablative doses delivered with modern conforma-
tional techniques, have improved the long-term survival of
cancer patients in recent years. Nevertheless, cytotoxic
chemotherapy remains one of the key therapeutic options, andClin Microbiol Infect 2015; 21: 583–590
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stream infection (BSI) continues to cause signiﬁcant mortality
among neutropenic patients in spite of adequate antibiotic
therapy and advances in shock management [1–3]. Crude
mortality rates of BSI in cancer patients vary from 12% to 42%
[4].
The role played by the rapid initiation of empirical antibiotic
therapy for febrile neutropenia in reducing mortality is now
undisputed. In addition, some studies have reported that inap-
propriate empirical antibiotic treatment is associated with
worse outcome and has a signiﬁcant impact on survival [5].
However, only a few studies have explored other factors that
are hypothetically associated with poor prognosis, and most of
them were published before the development of antibiotic
resistance became a major problem [6–10]. Consequently, a
number of important uncertainties remain, and to our knowl-
edge, none of these studies has analysed prognostic factors
while stratifying haematologic malignancies and solid tumours as
separate groups in order to compare them.
The aim of the present study was to identify prognostic
factors amenable to medical intervention in neutropenic pa-
tients with BSI in these two different groups of cancer patients,
with the ultimate goal being to improve outcomes.Materials and methodsSetting and study design
We conducted a prospective observational study in a 200-bed
cancer referral centre for adults in Barcelona, Spain. From 1
January 2006 to 31 December 2013, all hospitalized adult
neutropenic cancer patients with at least one episode of BSI
were included in the study. Episodes occurring within the ﬁrst 4
weeks from the ﬁrst BSI episode were considered relapses and
were therefore excluded. However, a second episode occur-
ring after 4 weeks from the ﬁrst episode was considered a
different episode and was therefore included. Data regarding
baseline characteristics, clinical features, causative organisms,
antibiotic therapy and outcomes were collected in a speciﬁc
database. Factors inﬂuencing mortality were assessed in two
groups of patients: those with haematologic malignancies and
those with solid tumours.
From January 2006 to June 2011, no universal antibacterial
prophylaxis was provided during neutropenia. Since July 2011,
ciproﬂoxacin was provided to patients receiving allogeneic
haematopoietic stem cell transplant. During the study period,
the most frequent empirical antibiotic therapy for febrile neu-
tropenia was cefepime (or imipenem) plus amikacin (within the
ﬁrst 48 hours).Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectThe study was approved by the ethics committee of our
institution.
Deﬁnitions
Advanced solid neoplasm was considered in patients with
metastatic disease (stage IV) and for some stage III tumours
(lung, pancreas, gastric, esophagus and urothelial) not amenable
to treatment or in progressive outbreak during treatment.
Breast and prostate cancer affected with bone metastasis,
colorectal cancer with resectable hepatic and lung metastasis
and metastatic germinal tumours were excluded.
Advanced haematologic neoplasm was deﬁned as the
absence of complete remission in patients with leukaemia plus
the development of new lesions, enlargement of a measurable
lesion while receiving chemotherapy or premature termination
of chemotherapy due to other evidence of failure.
Comorbidities were deﬁned as the presence of one or more
of the following diseases: heart or hepatic disease, diabetes
mellitus, renal failure and cerebrovascular disease. Neutropenia
was deﬁned as an absolute neutrophil count 500 neutrophils/
μL. Prior antibiotic therapy was deﬁned as the receipt of any
systemic antibiotic for >48 hours in the previous month. BSI
was considered to be nosocomially acquired, healthcare related
or community acquired, applying criteria described previously
[11].
Corticosteroid therapy was recorded when a patient was
receiving corticosteroids at the time of the BSI episode or in
the previous month. Shock was deﬁned as a systolic pressure
<90 mm Hg that was unresponsive to ﬂuid treatment and/or
which required vasoactive drugs. The Multinational Association
for Supportive Care in Cancer (MASCC) score was calculated
as described elsewhere [12].
BSI caused by coagulase-negative staphylococci (CNS) was
considered to be signiﬁcant when the same species grew in at
least two blood cultures or in one blood culture and at one
other site.
The following Gram-negative bacilli (GNB) were considered
to be multidrug resistant (MDR): (a) extended-spectrum
β-lactamase (ESBL)-producing Enterobacteriaceae, (b) AmpC
cephalosporinase hyperproducing Enterobacteriaceae, (c) mi-
croorganisms with intrinsic resistance mechanisms, such as
Stenotrophomonas maltophilia, and (d) MDR strains of Pseudo-
monas aeruginosa and Acinetobacter baumannii. MDR GNB were
deﬁned as those resistant to at least three classes of antibiotics:
carbapenems, ureidopenicillins, cephalosporins (ceftazidime and
cefepime), monobactams, aminoglycosides and ﬂuo-
roquinolones [13].
Empirical antibiotic therapy was considered inadequate if the
treatment regimen did not include at least one antibiotic that
was active in vitro against the infecting microorganism beforeious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 583–590
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producing Enterobacteriaceae BSI, treatment with an oxy-
imino-β-lactam was considered inadequate, regardless of the
minimum inhibitory concentration. Empirical antibiotic combi-
nation therapy was deﬁned as the empirical use of antibiotics
from two different families. Time to adequate antibiotic therapy
was also analysed.
Patients receiving corticosteroids who presented with se-
vere sepsis or septic shock were initially provided an increased
dose of these drugs. Corticosteroids were tapered when se-
vere sepsis or septic shock resolved.
The overall case-fatality rate was deﬁned as death by any
cause within 30 days of onset of BSI.
Microbiology analysis
Two sets of two blood samples (BACTEC Plus Aerobic and
Anaerobic; BD), taken 30 minutes apart, and each containing 8
to 10 mL of blood, were drawn from patients who presented a
temperature of 38°C or when BSI was suspected on the basis
of any clinical sign or symptom. Microbial identiﬁcation was
performed using commercially available panels (MicroScan
(Siemens) or Vitek (bioMérieux)) or by standard biochemical
and/or enzymatic test or by matrix-assisted laser desorption-
ionization time-of-ﬂight analysis (Bruker Daltonics).
Antibiotic susceptibility was tested using the microdilution
method following Clinical Laboratory Standard Institute (CLSI)
guidelines. The screening of MDR phenotypes including
methicillin-resistant Staphylococcus aureus, ampicillin- and
vancomycin-resistant enterococci, ESBL production and car-
bapenemase production was conducted according to CLSI
recommendations [14].
Statistical analysis
Continuous variables were compared by the Mann-Whitney U
test or Student’s t test. Qualitative variables were compared by
the chi-square test. Odds ratios (OR) and 95% conﬁdence in-
tervals (CI) were calculated. A p value of <0.05 was considered
statistically signiﬁcant. Multivariate conditional logistic regres-
sion analysis of factors potentially associated with mortality
included all statistically signiﬁcant variables in the univariate
analysis, sex and age, as well as all clinically important variables
[15]. The analysis was performed by using the stepwise logistic-
regression model in SPSS 15.0 (IBM). The Wald test was used
for the selection of the variables.ResultsOf 602 episodes of BSI in neutropenic patients, 510 occurred in
patients with haematologic malignancies and 92 in patients withClinical Microbiology and Infection © 2015 European Society of Clinical Microbiologysolid tumours. The overall incidence of BSI was 7.16 episodes/
1000 hospital stays for haematologic patients and 0.95 episodes/
1000 hospital stays for patients with solid tumours (p < 0.001).
Table 1 shows baseline characteristics of neutropenic pa-
tients, and Table 2 details microbiologic differences between
the two groups.
In the group of patients with haematologic malignancies,
empirical antibiotic therapy was more often appropriate in
patients receiving antibiotic combination therapy than in those
who received antibiotic monotherapy (80.7% vs. 66.1%; OR,
2.1; 95% CI, 1.4–3.4; p < 0.001). In the group of patients with
solid tumours, the treatment was considered appropriate in
90.7% of the patients treated with antibiotic combination, while
it was appropriate in 68.7% of those treated with monotherapy
(OR, 4.48; 95% CI, 1.2–16.6; p 0.032).
In patients with haematologic malignancies, after applying the
multivariate analysis, intensive care unit (ICU) admission (OR,
15.2; 95% CI, 5.4–42.7), advanced neoplasm (OR, 8.7; 95% CI,
2.9–25.7), corticosteroid therapy (OR, 7.0; 95% CI, 3–16.4),
MASCC risk score of <21 (OR, 3.1; 95% CI, 1.3–7.4) and MDR
GNB BSI (OR, 3.8; 95% CI, 1.2–11.8) were the only variables
independently associated with higher case fatality. Among 37
patients with BSI caused by a MDR GNB, 26 (70.3%) received
inadequate empirical antibiotic therapy (p < 0.001). Only three
patients (7.9%) with BSI caused by a MDR GNB had received
prophylaxis with ciproﬂoxacin. Furthermore, among 25 pa-
tients who underwent an allogenic hematopoietic stem cell
transplantation and developed BSI from July 2011 to December
2013, 13 patients received quinolone prophylaxis before the
onset of BSI, and 12 did not. There was no signiﬁcant difference
in mortality when comparing these two groups of patients (one
(7.7%) of the 13 patients who received quinolone prophylaxis
died, vs. ﬁve (41.7%) of the 12 patients not receiving prophy-
laxis who also died; p 0.073).
On the other hand, patients with CNS BSI (OR, 0.04; 95%
CI, 0.004–0.5) and those treated with combination empiric
antibiotic therapy (OR, 0.1; 95% CI, 0.05–0.3) were more likely
to survive (Table 3).
Table 4 shows the variables found to be signiﬁcantly asso-
ciated with case-fatality rate in the group of patients with solid
tumours: septic shock at presentation (OR, 14.3; 95% CI,
3.2–63.8), corticosteroid therapy (OR, 10; 95% CI, 2.3–44)
and advanced neoplasm (OR, 7.8; 95% CI, 1.4–41.4).DiscussionRisk factors for a higher case-fatality rate identiﬁed in both
groups of cancer patients were the presence of an advanced
neoplasm and corticosteroid therapy. Patients withand Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 583–590
TABLE 1. Baseline characteristics of 602 episodes of BSI in neutropenic patients with haematologic malignancies or solid tumours
Characteristic
Haematologic malignancies,
n (%) Solid tumours, n (%)
p(n [ 510) (n [ 92)
Age (y), median (range) 57 (19–89) 60.5 (14–79) 0.004
Male sex 314 (61.6) 56 (60.9)
Underlying disease
Acute leukemia 307 (60.2)
Lymphoma 96 (18.8)
Chronic leukemia 35 (6.9)
Multiple myeloma 32 (6.3)
Myelodysplastic syndrome 17 (3.3)
Lung tumour 24 (26.1)
Breast tumour 17 (18.5)
Urinary tract tumour 9 (9.8)
Gynecologic tumour 8 (8.7)
Head and neck tumour 7 (7.6)
Lower gastrointestinal tumour 5 (5.4)
Sarcoma 5 (5.4)
Other 23a (4.5) 19b (20.6)
Advanced neoplasm 40 (7.9) 58 (63) <0.001
Haematopoietic stem cell transplant 129 (25.3) 1 (1.1) <0.001
MASCC score <21 152 (31.9) 42 (49.4) 0.002
Comorbiditiesc 138 (27.1) 32 (34.8)
Community-acquired BSI 12 (2.4) 13 (14.1) <0.001
Previous antibiotic therapy (1 month) 287 (56.3) 27 (29.3) <0.001
Vascular catheter 439 (86.1) 29 (31.5) <0.001
Previous chemotherapy 453 (89) 90 (97.8) 0.003
Corticosteroid therapy 130 (25.5) 38 (41.3) 0.002
Prophylaxis with quinolones 36 (7) 1 (1.1)
Clostridium difﬁcile coinfection 7 (1.4) 0 (0)
Prolonged neutropenia before BSI (>10 days) 117 (23.9) 3 (3.8) <0.001
Grade III– IV mucositis 66 (13) 11 (12)
Source of BSI
Endogenous source 263 (51.6) 25 (27.2) <0.001
Catheter infection 127 (24.9) 8 (8.7) <0.001
Mucositis 30 (5.9) 4 (4.3)
Unknown origin 27 (5.3) 4 (4.3)
Pneumonia 21 (4.1) 23 (25) <0.001
Urinary tract infection 11 (2.2) 9 (9.8) 0.001
Abdominal source 6 (1.2) 10 (10.9) <0.001
Other sources d25 (4.9) 9 (9.8)e
Septic shock 52 (10.2) 27 (29.3) <0.001
Empirical antibiotic therapy 495 (97.1) 92 (100)
Combination antibiotic empirical therapy 369 (74.8) 76 (82.6)
Cefepime + amikacin 310 (62.6) 66 (71.7)
Imipenem + amikacin 19 (3.8) 2 (2.2)
Vancomycin + aztreonam 9 (1.8) 3 (3.2)
Amoxicillin-clavulanate + ciproﬂoxacin 0 (0) 2 (2.2)
Other 31 (6.3) 3 (3.2)
Monotherapy 126 (25.5) 16 (17.4)
Imipenem 45 (9.1) 5 (5.4)
Cefepime 26 (5.3) 1 (1.1)
Vancomycin 22 (4.4) 1 (1.1)
Inadequate empirical antibiotic therapy 127 (25) 12 (13) 0.007
Growth factors 131 (26.2) 35 (38.9) 0.011
ICU admission 54 (10.6) 2 (2.2) 0.004
Invasive mechanical ventilation 30 (6) 0 (0) 0.005
Overall case fatality 61 (12.1) 33 (36.3) <0.001
BSI, bloodstream infection; ICU, intensive care unit; MASCC, Multinational Association for Supportive Care in Cancer.
aMedullary aplasia (n = 9), Waldenstrom macroglobulinemia (n = 6), myeloﬁbrosis (n = 2), granulocytic sarcoma (n = 4), Sézary syndrome (n = 1), mycosis fungoides (n = 1).
bHepatobiliary tumours (n = 3), gastric tumours (n = 2), central nervous system tumours (n = 3), prostate tumours (n = 2), unknown origin (n = 2), carcinoid (n = 1), germinal
(n = 3), thymoma (n = 1).
cComorbidities are deﬁned as the presence of one or more of the following diseases: heart or hepatic disease, diabetes mellitus, renal failure and cerebrovascular disease.
dCholangitis (n = 2), otorhinolaryngologic infection (n = 4), skin and soft tissue infections (n = 5), perianal infection (n = 13), disseminated infection (n = 1).
eCholangitis (n = 3), skin and soft tissue infections (n = 4), perianal infection (n = 1), endocarditis (n = 1).
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a fact related to the low performance status frequently present
in these patients. Corticosteroids play a decisive role in the
immune function as well as in systemic cytokine expression.
Moreover, chronic treatment can induce adrenal atrophy and
insufﬁcient adrenal response to control the inﬂammatory situ-
ation [16].
ICU admission was found to be one of the most important
risk factors associated with mortality in patients withClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infecthaematologic malignancies; this was not the case for patients
with solid tumours. This ﬁnding may be due to the fact that
haematologic patients were more frequently admitted to the
ICU and more often required invasive mechanical ventilation.
The question of whether or not patients with advanced solid
tumours should be admitted to the ICU remains a matter of
debate; recently, there has been a trend towards admitting
patients to the ICU according to the severity of the acute illness
rather than to factors related to the neoplasm [17].ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 583–590
TABLE 2. Microorganisms isolated in 602 episodes of BSI in neutropenic patients with haematologic malignancies or solid tumours
Microorganism
Haematologic malignancies (n [ 510) Solid tumours (n [ 92)
Episodes, n (%) Deaths, n (%) Episodes, n (%) Deaths, n (%)
Gram-positive bacteria 211 (41.4) 16 (7.6) 27 (29.35) 7 (25.9)
coagulase-negative staphylococci 95 (45) 4 (4.2) 6 (22.2) 0 (0)
Staphylococcus aureus 25 (11.84) 1 (4) 5 (18.5) 1 (20)
MRSA 7 (28) 1 (14.3) 1 (20) 0 (0)
Viridans group streptococci 40 (19) 6 (15) 6 (22.2) 1 (16.7)
Streptococcus pneumoniae 11 (5.2) 2 (18.2) 3 (11.1) 1 (33.33)
Enterococcus spp. 46 (4.3) 9 (19.6) 2 (50) 1 (50)
Other 2 (0.9) 0 (0) 1 (0.5) 0 (0)
Gram-negative bacilli 250 (49) 33 (13.2) 55 (59.8) 23 (41.8)
Escherichia coli 128 (51.2) 13 (10.2) 20 (21.7) 10 (50)
Klebsiella pneumoniae 55 (22) 9 (16.4) 12 (21.8) 6 (50)
Pseudomonas aeruginosa 54 (21.6) 9 (16.7) 24 (43.6) 10 (41.7)
Enterobacter spp. 23 (9.2) 3 (13) 2 (3.6) 1 (50)
Other 4 (1.6) 2 (50) 3 (5.4) 1 (0.2)
MDR Gram-negative bacillia 38 (15.2) 12 (31.6) 2 (3.6) 2 (100)
ESBL-producing Enterobacteriaceae 23 (60.5) 6 (26.1) 2 (100) 2 (100)
Stenotrophomonas maltophilia 9 (23.7) 4 (44.4)
AmpC-producing Enterobacteriaceae 3 (7.9) 0 (0)
MDR Pseudomonas aeruginosa 2 (5.3) 1 (50)
Polymicrobialb 50 (9.8) 9 (18) 9 (9.8) 4 (44.4)
Anaerobes 14 (2.8) 4 (28.6) 2 (2.2) 0 (0)
BSI, bloodstream infection; CNS, coagulase-negative staphylococci; ESBL, extended-spectrum β-lactamase; MDR, multidrug resistant; MRSA, methicillin-resistant Staphylococcus
aureus.
aMDR Gram-negative organisms are included in the total of Gram-negative organisms.
bPolymicrobial bacteremias include episodes with more than one microorganism.
CMI Marín et al. Prognosis of neutropenic cancer with bacteremia 587An important ﬁnding in our study was that MDRGNB BSI
was an independent predictor of the case-fatality rate in pa-
tients with haematologic malignancies. The odds of death were
nearly four times greater in this group of patients than in those
with susceptible strains. This ﬁnding is in line with that of
Tumbarello et al. [4], who conducted a retrospective study of
mortality risk factors in bacteremic patients with haematologic
malignancies; it should be noted, however, that their study
population included patients with and without neutropenia. In
our patients, MDR GNB were more frequently isolated in the
group of haematologic malignancies than in those with solid
tumours, mainly due to ESBL-producing Enterobacteriaceae.
Haematologic patients were more likely to have received pre-
vious antibiotics than were patients with solid tumours—this
being a well-known risk factor for development of resistance
[18]. The emergence of MDRGNB has become a major health
problem worldwide and is of particular concern among
immunosuppressed patients with cancer [18–20]. A relation-
ship between infection with resistant bacteria and poor
outcome has been reported in several settings, mainly due to a
delay in the initiation of an adequate antibiotic therapy [19–22].
This relationship was not found in our patients with solid
tumours.
A MASCC risk score of <21 was found to be a mortality risk
factor in neutropenic patients with haematologic malignancies.
Consistent with the results of the present study, Klastersky
et al. [2] reported higher mortality rates and a greater number
of complications in this subgroup of patients. In this context,Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiologyanother scoring system has recently been developed and vali-
dated speciﬁcally for patients with haematologic malignancies
and BSI [23].
We did not ﬁnd an association between inadequate empirical
antibiotic therapy and poorer outcome in either of the two
groups. However, it should be noted that most bacteremic
episodes in patients receiving inadequate therapy were caused
by CNS. In fact, CNS BSI was found to be a predictor of lower
mortality in patients with haematologic malignancies, as
mentioned in other studies [2,10]. These organisms are
frequently resistant to the usual empirical treatment, but they
rarely cause death [24]. Moreover, a short delay in appropriate
deﬁnitive antimicrobial therapy may not be associated with
higher mortality if antimicrobial therapy is promptly adjusted
according to the susceptibility results. In this regard, in our
hospital, modern microbiologic diagnostic methods are being
used which allow early reporting of the results.
Interestingly, in patients with haematologic malignancies,
empirical antibiotic combination therapy was found to be a
protective factor. In recent decades, monotherapy has been
considered to be as effective as aminoglycoside-containing
combinations [25]. However, as a result of increasing resis-
tance, recent guidelines recommend a de-escalation approach
with initial broad-spectrum antibiotics or combinations in
those patients with known prior colonization or infection
with resistant pathogens as well as in centres where resistant
pathogens are prevalent, or in complicated presentations
[26].and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 583–590
TABLE 3. Risk factors for the overall case-fatality rate of 510 episodes of BSI in neutropenic patients with haematologic
malignancies according to univariate and multivariate analysis
Risk factor n
Dead Alivea Univariate analysis Multivariate analysisb
(n [ 61) (n [ 445) OR (95% CI) p OR (95% CI) p
Age, y, median (range) 61 (21–84) 57 (19–89) 1 (1.0–1.04) 0.035 —
Male sex 311 31 (10) 280 (90) 0.6 (0.4–1) 0.069
Advanced neoplasm 39 13 (33.3) 26 (66.7) 4.46 (2.2–9.3) <0.001 8.7 (2.9–25.7) <0.001
Haematopoietic stem cell transplant 129 12 (9.3) 117 (90.7) 0.7 (0.7–1.4) 0.29
MASCC score <21 150 37 (24.7) 113 (75.3) 6.7 (3.5–12.7) <0.001 3.1 (1.3–7.4) 0.01
Comorbiditiesc 136 24 (17.6) 112 (82.4) 1.9 (1.1–3.4) 0.019
Study periodd (July 2011–December 2013) 206 26 (12.6) 180 (87.4) 1.09 (0.6–1.9) 0.78
Previous monoclonal antibody therapy 74 12 (16.2) 62 (83.8) 1.5 (0.8–3.0) 0.23
Previous cyclosporine therapy 49 5 (10.2) 44 (89.8) 0.81 (0.3–2.1) 0.68
Previous ﬂudarabine therapy 91 13 (14.3) 78 (85.7) 1.28 (0.7–2.5) 0.46
Antacid therapy 443 53 (12.0) 390 (88.0) 0.92 (0.4–2.9) 0.87
Statin therapy 40 6 (15) 34 (85) 1.32 (0.5–3.3) 0.65
ACE inhibitor therapy 50 5 (10) 45 (90) 0.8 (0.3–2.1) 0.65
Acetylsalicylic acid therapy 14 0 (0) 14 (100) 0.87 (0.8–0.9) 0.39
β-Blocker therapy 32 7 (21.9) 25 (78.1) 2.2 (0.9–5.3) 0.089
Clostridium difﬁcile coinfection 7 0 (0) 7 (100) 0.87 (0.8–0.9) 1.0
Corticosteroid therapy 128 32 (25) 96 (75) 4.0 (2.3–6.9) <0.001 7.00 (3–16.4) <0.001
Causative agents of BSI
Gram positive 211 16 (7.6) 195 (92.4) 0.5 (0.2–0.8) 0.009 Not included in model
Coagulase-negative staphylococci 95 4 (4.2) 91 (95.8) 0.3 (0.1–0.8) 0.009 0.04 (0.004–0.5) 0.009
Staphylococcus aureus 25 1 (4) 24 (5.4) 0.3 (0.04–2.2) 0.34
Viridans group streptococci 40 6 (15) 34 (85) 1.3 (0.5–3.3) 0.61
Streptococcus pneumoniae 11 2 (18.2) 9 (81.8) 1.6 (0.3–7.8) 0.63
Enterococcus spp. 46 9 (19.6) 37 (80.4) 2 (0.9–4.3) 0.08
Gram negative 250 33 (13.2) 217 (86.8) 1.2 (0.7–2.1) 0.43
Escherichia coli 128 13 (10.2) 115 (89.8) 0.8 (0.4–1.5) 0.44
Klebsiella pneumoniae 55 9 (16.4) 46 (83.6) 1.5 (0.7–3.2) 0.30
Pseudomonas aeruginosa 54 9 (16.7) 45 (83.3) 1.5 (0.7–3.3) 0.27
Enterobacter spp. 23 3 (13.04) 20 (86.96) 1.1 (0.3–3.8) 0.75
MDR GNB 38 12 (31.6) 26 (68.4) 3.9 (1.9–8.2) <0.001 3.8 (1.2–11.8) 0.019
ESLB-producing Enterobacteriaceae 23 6 (26.1) 17 (73.9) 2.7 (1.0–7.2) 0.047
Polymicrobial 50 9 (18) 41 (82) 1.7 (0.8–3.7) 0.17
Anaerobes 14 4 (28.6) 10 (71.4) 3.05 (0.9–10) 0.076
Source of BSI
Catheter infection 126 7 (5.6) 119 (94.4) 1.0
Pneumonia 20 9 (45) 11 (55) 13.9 (4.3–44.4) <0.001
Unknown origin 27 6 (22.2) 21 (77.8) 4.9 (1.5–15.9) 0.009
Abdominal source 6 1 (16.7) 5 (83.3) 3.4 (0.3–33.2) 0.3
Endogenous source 263 29(11.1) 234 (88.9) 2.1 (0.9–4.9) 0.087
Urinary tract infection 10 1 (10) 9 (90) 1.9 (0.2–17.1) 0.6
Other sources 54 8 (13.1) 46 (10.3) 3 (1–8.6) 0.047
Septic shock 51 20 (39.2) 31 (60.8) 6.51 (3.4–12.4) <0.001
Persistent BSIe 29 8 (27.6) 21 (72.4) 4 (1.6–9.6) <0.001
Inadequate empirical antibiotic therapy 378 46 (12.2) 332 (87.8) 1.02 (0.5–1.9) 0.93
Empirical antibiotic combination therapy 366 31 (8.5) 335 (91.5) 0.3 (0.2–0.6) <0.001 0.1 (0.05–0.3) <0.001
Days before adequate antibiotic therapy 0 (0–4) 0 (0–7) 1.1 (0.8–1.4) 0.56
Growth factors 129 21 (16.3) 108 (83.7) 1.6 (0.9–2.9) 0.09
ICU admission 53 29 (54.7) 24 (45.3) 16 (8.3–30.4) <0.001 15.2 (5.4–42.7) <0.001
Invasive mechanical ventilation 30 23 (76.7) 7 (23.3) 40.5 (16.2–100.9) <0.001 Not included in model
ACE, angiotensin-converting enzyme; BSI, bloodstream infection; ESLB, extended-spectrum β-lactamase; GNB, Gram-negative bacilli; ICU, intensive care unit; MASCC, Multinational
Association for Supportive Care in Cancer; MDR, multidrug resistant.
aWe excluded four patients from the logistic regression analysis because we could not ascertain whether they were still alive 30 days from the onset of BSI.
bMultivariate logistic regression analysis included all statistically signiﬁcant variables in the univariate analysis as well as sex and age.
cComorbidities included presence of one or more of the following: chronic obstructive pulmonary disease, heart or hepatic disease, diabetes mellitus, renal failure and cerebro-
vascular disease.
dStudy period when ciproﬂoxacin prophylaxis was provided to patients receiving allogenic haematopoietic stem cell transplantation.
eMore than 48 hours since beginning of appropriate therapy.
588 Clinical Microbiology and Infection, Volume 21 Number 6, June 2015 CMIIn patients with solid tumours, shock at onset of BSI was
found to be important risk factor associated with mortality.
This result is in agreement with previous studies which have
also documented the ominous prognosis of shock, in which the
speed and appropriateness of therapy administered in the initial
hours are likely to inﬂuence outcome [8,26–28]. However, this
risk factor was not found to be associated with the case-fatality
rate in our haematologic patients.
The strengths of the current study include the prospective
nature of the cohort, the large number of BSI episodes in
neutropenic cancer patients and the comprehensive dataClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectcollection by means of a uniform protocol. However, there are
some limitations that should be acknowledged. Firstly, this is a
single-centre study in a particular geographical area. Secondly,
as with any observational study, there is a potential for residual
confounding. Finally, the criteria for ICU admission in our
hospital are not homogeneous.
In conclusion, certain prognostic factors may help to detect
those patients at higher risk of death. Medical intervention
addressing some of these factors might improve the outcome of
BSI in neutropenic patients with haematologic malignancies or
solid tumours.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 583–590
TABLE 4. Risk factors for the overall case-fatality rate of 92 episodes of BSI in neutropenic patients with solid tumours according to
univariate and multivariate analysis
Risk factor na
Death, n (%) Alive, n (%) Univariate analysis Multivariate analysisb
(n [ 33) (n [ 58) OR (95% CI) p OR (95% CI) p
Age (y), median (range) 60.0 (37–79) 60.5 (14–79) 10.3 (0.9–1.1) 0.18
Male sex 55 16 (29.1) 39 (70.9) 0.5 (0.2–1.1) 0.08
Advanced neoplasm 57 26 (45.6) 31 (54.4) 3.2 (1.2–8.6) 0.016 7.8 (1.4–41.4) 0.017
MASCC score <21 41 22 (53.7) 19 (46.3) 5.6 (2.2–16.4) <0.001
Comorbiditiesc 32 14 (43.8) 18 (56.2) 1.6 (0.7–4) 0.27
Antacid therapy 64 24 (37.5) 40 (62.5) 1.5 (0.5–4.0) 0.47
Statin therapy 6 1 (16.7) 5 (83.3) 0.3 (0.04–2.9) 0.3
ACE inhibitor therapy 9 3 (33.3) 6 (66.7) 0.9 (0.2–3.8) 0.86
Acetylsalicylic acid therapy 6 3 (50) 3 (50) 1.9 (0.3–9.8) 0.46
β-Blocker therapy 5 3 (60) 2 (40) 2.8 (0.4–18) 0.25
Clostridium difﬁcile coinfection 0 0 (0) 0 (0)
Corticosteroid therapy 37 22 (59.5) 15 (40.5) 5.7 (2.3–14.6) <0.001 10 (2.3–44) 0.002
Causative agents of BSI
Gram positive 27 7 (25.9) 20 (74.1) 0.5 (0.2–1.4) 0.18
Coagulase-negative staphylococci 6 0 (0) 6 (100) 0.083
Staphylococcus aureus 5 1 (20) 4 (80) 0.4 (0.04–3.9) 0.65
Viridans group streptococci 6 1 (16.7) 5 (83.3) 0.3 (0.03- 3.1) 0.42
Streptococcus pneumoniae 3 1 (33.3) 2 (66.7) 0.9 (0.1–10.0) 1.0
Enterococcus spp. 2 1 (50) 1 (50) 1.8 (0.1–29.4) 1.0
Gram-negative 55 23 (41.8) 32 (58.2) 1.9 (0.8–4.6) 0.17
Escherichia coli 20 10 (50) 10 (50) 2.1 (0.8–5.7) 0.14
Klebsiella pneumoniae 12 6 (50) 6 (50) 1.9 (0.6–6.6) 0.29
Pseudomonas aeruginosa 24 10 (41.7) 14 (58.3) 1.4 (0.5–3.6) 0.52
Enterobacter spp. 2 1 (50) 1 (50) 1.8 (0.1–29.4) 1.0
MDR GNB 2 2 (100) 0 (0) 0.12
ESLB-producing Enterobacteriaceae 2 2 (100) 0 (0) 0.12
Polymicrobial 9 4 (44.4) 5 (55.6) 1.5 (0.4–5.9) 0.59
Anaerobes 2 0 (0) 2 (100) 0.53
Source of BSI
Catheter infection 8 1 (12.5) 7 (87.5) 0.28
Pneumonia 23 12 (52.2) 11 (47.8) 7.6 (0.8–72.4) 0.08
Unknown origin 4 4 (100) 0 (0) 1.1E+010 0.99
Abdominal source 9 5 (55.6) 4 (44.4) 8.7 (0.73–103.8) 0.09
Endogenous source 25 9 (36) 16 (64) 3.9 (0.4–37.3) 0.23
Urinary tract infection 9 0 (0) 9 (100) 0.00 0.99
Other source 13 2 (6.1) 11 (19) 1.3 (0.1–16.8) 0.85
Septic shock 27 20 (74.1) 7 (25.9) 11.2 (3.9–32.2) <0.001 14.3 (3.2–63.8) <0.001
Persistent BSId 2 1 (50) 1 (50) 2.5 (0.1–41.6) 0.51
Inadequate empirical antibiotic therapy 12 5 (41.7) 7 (58.3) 0.8 (0.2–2.6) 0.75
Empirical antibiotic combination therapy 76 26 (34.2) 50 (65.8) 0.6 (0.2–1.8) 0.36
Days before adequate antibiotic therapy 0 (0–5) 0 (0–1) 0.6 (0.3–1.4) 0.27
Growth factors 35 12 (34.3) 23 (65.7) 0.9 (0.4–2.3) 0.93
ICU admission 2 1 (50) 1 (50) 1.8 (0.1–29.4) 0.68
Invasive mechanical ventilation 0 0 (0) 0 (0)
ACE, angiotensin-converting enzyme; BSI, bloodstream infection; ESLB, extended-spectrum β-lactamase; GNB, Gram-negative bacilli; ICU, intensive care unit; MASCC, Multinational
Association for Supportive Care in Cancer; MDR, multidrug resistant.
aWe excluded one patient from the logistic regression analysis because we could not ascertain whether he was still alive 30 days from onset of BSI.
bMultivariate logistic regression analysis include all signiﬁcant variables in the univariate analysis as well as sex and age.
cComorbidities include presence of one or more of the following diseases: chronic obstructive pulmonary disease, heart or hepatic disease, diabetes mellitus, renal failure and
cerebrovascular disease.
dMore than 48 hours since beginning appropriate therapy.
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